Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 644 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Diseases Clear all
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears

NCT01614847
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial tears
Drug
Lead sponsor
Thomas O Salmon, OD, PhD
Other
Eligibility
18 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 1 Interventional

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

NCT03926286
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
FMP-30
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 23, 2026, 12:58 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

NCT04172961
View directory record Official record
Conditions
Dry Eye
Interventions
nanomicellular cyclosporine 0.09%, Lifitegrast
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

NCT03019627
View directory record Official record
Conditions
Dry Eye
Interventions
NGF, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

NCT06400459
View directory record Official record
Conditions
Dry Eye Disease
Interventions
IVW-1001 Ophthalmic Eyelid Wipe 0.1%, IVW-1001 Ophthalmic Eyelid Wipe 0.2%, IVW-1001 Placebo
Drug
Lead sponsor
IVIEW Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

NCT03452397
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL), Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 4 Interventional

CEQUA for Sjogren's Syndrome Dry Eye

NCT04835623
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes, Sjogren's Syndrome
Interventions
Cyclosporine 0.09% Ophthalmic Solution
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

NCT03846453
View directory record Official record
Conditions
Dry Eye
Interventions
HL036 Ophthalmic Solution, Placebo
Biological
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Phoenix, Arizona • Newport Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Not applicable Interventional

Evaluation of Low-Level Light Therapy on Meibomian Glands Study

NCT05859295
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Red Low-Level Light Therapy
Device
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 23, 2026, 12:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Gunnar Computer Glasses on Viewing Comfort and Performance

NCT02925884
View directory record Official record
Conditions
Dry Eye, Eye Strain, Visual Acuity, Color Perception
Interventions
Gunnar OTC Glasses
Device
Lead sponsor
Pacific University
Other
Eligibility
18 Years to 42 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Forest Grove, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 23, 2026, 12:58 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics

NCT01450787
View directory record Official record
Conditions
Dry Eyes
Interventions
Not listed
Lead sponsor
COA Research Foundation, INC
Other
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04735393
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Reproxalap Ophthalmic Solution (0.25%), Placebo Comparator
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 23, 2026, 12:58 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Tears Substitutions and Their Effects on Higher Order Aberrometery

NCT00812721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Preservative Free Saline, Optive, Refresh Moderate/Severe, Systane, Systane Ultra
Other
Lead sponsor
Gina Rogers
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 12:58 PM EDT
Completed No phase listed Observational

Portable Endoscopic Camera System Using Modified Action Camera for Endoscopic Sinunasal Examination

NCT07289854
View directory record Official record
Conditions
Nasolacrimal Duct Obstruction, Nasolacrimal Tract Obstruction
Interventions
Modified Portable Endoscopic Camera
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Green Tea Lozenges for the Management of Dry Mouth

NCT01647737
View directory record Official record
Conditions
Xerostomia, Sjogren Syndrome, Dry Mouth
Interventions
MighTeaFlow, Xylitol
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 2 Interventional

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

NCT04968912
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Placebo, Nipocalimab, Standard of Care Treatment
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Not applicable Interventional Results available

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

NCT03417505
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
Device
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Sacramento, California • Fort Lauderdale, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 1 Interventional

A Study of AG-80308 in Dry Eye Patients

NCT05372107
View directory record Official record
Conditions
Dry Eye Disease
Interventions
AG-80308
Drug
Lead sponsor
Allgenesis Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Newport Beach, California • Raynham, Massachusetts • Clinton, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 23, 2026, 12:58 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser

NCT01441895
View directory record Official record
Conditions
Cataract, Dry Eye
Interventions
Not listed
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 23, 2026, 12:58 PM EDT
Completed Not applicable Interventional Results available

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

NCT06444516
View directory record Official record
Conditions
Dry Eye Disease
Interventions
FID123300 ocular lubricant
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Maitland, Florida • Orlando, Florida • Franklin Park, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 23, 2026, 12:58 PM EDT
Withdrawn Phase 2 Interventional

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

NCT02027298
View directory record Official record
Conditions
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 23, 2026, 12:58 PM EDT